0001104659-18-006228.txt : 20180202 0001104659-18-006228.hdr.sgml : 20180202 20180202160736 ACCESSION NUMBER: 0001104659-18-006228 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180131 FILED AS OF DATE: 20180202 DATE AS OF CHANGE: 20180202 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Broom Colin MD CENTRAL INDEX KEY: 0001289946 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37558 FILM NUMBER: 18570726 MAIL ADDRESS: STREET 1: 119 FRINGETREE DRIVE CITY: WEST CHESTER STATE: PA ZIP: 19380 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Nabriva Therapeutics plc CENTRAL INDEX KEY: 0001641640 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 56 FITZWILLIAM SQUARE CITY: DUBLIN STATE: L2 ZIP: 2 BUSINESS PHONE: (610) 816-6640 MAIL ADDRESS: STREET 1: 1000 CONTINENTAL DRIVE STREET 2: SUITE 600 CITY: KING OF PRUSSIA STATE: PA ZIP: 19406 FORMER COMPANY: FORMER CONFORMED NAME: Nabriva Therapeutics AG DATE OF NAME CHANGE: 20150507 4 1 a4.xml 4 X0306 4 2018-01-31 0 0001641640 Nabriva Therapeutics plc NBRV 0001289946 Broom Colin MD 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406 1 1 0 0 Chief Executive Officer Stock Options 2018-01-31 4 A 0 200000 0.00 A 2028-01-31 Ordinary Shares 200000 200000 D Restricted Stock Units 2018-01-31 4 A 0 67500 0.00 A 2021-01-31 Ordinary Shares 67500 67500 D The exercise price is $6.47 per share. The option award was granted on January 31, 2018. Vesting began on January 31, 2018 and ends on January 31, 2022. Twenty-five percent (25%) of the option award will vest on the one (1) year anniversary of the date of grant, and the remaining seventy-five percent (75%) of the option award will vest on a monthly pro-rata basis over the remaining vesting period. The restricted stock units shall convert into ordinary shares on a one-for-one basis upon vesting of the units. Vesting of the restricted stock unit award is subject to U.S. Food and Drug Administration ("FDA") approval of a new drug application ("NDA") for lefamulin. Fifty percent (50%) of the restricted stock unit award will vest upon FDA approval of an NDA for lefamulin, and the remaining fifty percent (50%) of the restricted stock unit award will vest on the one (1) year anniversary of such approval. If the FDA does not approve an NDA for lefamulin within two years of the grant date, the the restricted stock unit award will terminate in full. /s/ Robert Crotty, by power of attorney 2018-02-02